A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate efficacy, safety and tolerability of RO5045337 in
patients with liposarcoma who are eligible for debulking surgery. Prior to surgery, patients
will receive 2-3 cycles of RO5045337, orally for 10 days followed by 18 days of rest per
cycle. Anticipated time on study treatment is 3 months. Patients with an incomplete resection
may be treated for an additional 3 cycles with RO5045337.